Zydus Lifesciences signs exclusive agreement with MSN Laboratories for generic cancer treatment Cabozantinib tablets in the US market.

Zydus Lifesciences Ltd. signed an exclusive licensing and supply agreement with MSN Laboratories for generic cancer treatment drug Cabozantinib tablets in the US market. Zydus Lifesciences Global FZE, a wholly-owned subsidiary, entered the deal. MSN Laboratories will manufacture and supply the generic version of CABOMETYX after receiving regulatory approval. Zydus will be responsible for marketing, distribution, and sales in the US.

May 17, 2024
3 Articles